Morepen Laboratories Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹746 Cr +81.1% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
ML

Morepen Laboratories Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Morepen Laboratories Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹425Cr
−6.6% YoY
−8.8% QoQ
Net profit
₹11Cr
−69.4% YoY
−45% QoQ
Margin
6%
−5 pp YoY
−3 pp QoQ

Based on Morepen Laboratories Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹117
Market cap₹6.6K Cr
P/E56.4

The short version

Standalone Gross Revenue (Rs. Q1'FY26 Financials (Standalone):.

From Morepen Laboratories Ltd's Q1 FY26 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Standalone Gross Revenue (Rs. Crores):
  • Q1'FY25: 385
  • Q1'FY26 (Standalone): 395 (+2.6% YoY)
  • Q1'FY26 (Consolidated): 430
  • Pharma Business Total Revenue (Rs. Crores):
  • Q1'FY25: 250
  • Q1'FY26: 235 (-6% YoY)
  • Pharma API Revenue (Rs. Crores):
  • Q1'FY25: 224
  • Q1'FY26: 205 (-8.5% YoY)
  • Medical Devices Total Revenue (Rs. Crores):
  • Q1'FY25: 443
  • Q1'FY26: 496 (+12% YoY)
  • Glucometer Sales:
  • >1.06 million units sold in Q1'FY26 (72% YoY increase)
  • BP Meter Sales:
  • 3.37 crores revenue in Q1'FY26 vs. 3.17 crores in Q1'FY25
  • Outlook:

2 more points from Morepen Laboratories Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Plans to add 1000 Medical Representatives over 3 years to strengthen Pharma Business/RX segment (Page 26).
  • Pharma Business/Finished Dosages segment: Addition of 2 new product lines in Q1 FY26 indicating capacity/product portfolio expansion (Page 25).
  • Exploring new international markets for Medical Devices (Page 17), without disclosed investment amounts or timelines.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Morepen Laboratories Ltd said on order book & pipeline — free account, 30 seconds.

Morepen Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Morepen Laboratories Ltd Q1 FY26 results — key figures

Morepen Laboratories Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue425455-6.6%466-8.8%
Operating profit (EBITDA)2452-53.8%42-42.9%
Operating margin6%11%-5 pp9%-3 pp
Profit before tax1648-66.7%26-38.5%
Net profit (PAT)1136-69.4%20-45%
EPS (₹)0.200.71-71.8%0.37-45.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹89 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • Influx Healthtech (Q1 FY26)

    FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). Key concall takeaways from Influx Healthtech Ltd's Q1 FY26…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Morepen Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Morepen Laboratories Ltd Q1 FY26 results?

Standalone Gross Revenue (Rs. Q1'FY26 Financials (Standalone):.

What is Morepen Laboratories Ltd share price analysis?

Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 56.4 with a market cap of ₹6,625 Cr. Investors should review the full earnings analysis for detailed insights.

Is Morepen Laboratories Ltd planning capital expenditure?

Plans to add 1000 Medical Representatives over 3 years to strengthen Pharma Business/RX segment (Page 26).

Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.